Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical's Q1 Revenues Jump 67 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Response Biomedical today announced its first-quarter revenues rose 67 percent year over year to C$2.5 million ($2.6 million).

The C$2.5 million figure compares to C$1.5 million in revenues from a year ago. Clinical product revenues increased to C$1.8 million from C$1.2 million, while non-clinical product revenues climbed to C$266,285 from C$188,125 a year ago. Contract service revenues rose to C$448,104 from C$146,945 a year ago.

The firm's net loss for the quarter dropped 48 percent to C$1.4 million, or C$.04 per share, compared to C$2,660,048, or C$.10 per share.

As of March 31, Response Biomedical had a working capital balance of C$5.6 million.

In September, the Vancouver, British Columbia-based diagnostics test firm announced plans to cut costs by about C$2 million, and as part of that effort, said it would reduce its workforce by about 25 percent. In a statement today, CEO S. Wayne Kay said that the benefits of the restructuring effort had a material effect on the company's finances.

"The significant reduction in our workforce and the focus on our cardiac business are reflected not only in significantly reduced costs but also in increased sales volume," he said. The company did not disclose any of its costs, however, including R&D and SG&A spending.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more